# OnCo record lymphoma-tx-maintenance (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/lymphoma-tx-maintenance/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "lymphoma-tx-maintenance" ;
  schema:name "Maintenance and consolidation in lymphoma: where it works and where it does not"@en ;
  schema:alternateName "Rituximab maintenance"@en, "Lenalidomide maintenance"@en, "Brentuximab consolidation"@en ;
  schema:description "After the main treatment, some lymphomas are given a lower-intensity drug for months or years to hold the remission. It lengthens remission in follicular and mantle cell lymphoma but has never been shown to lengthen life, so it is a trade against two years of infusions and infections."@en ;
  schema:url <https://onco.cc/terms/lymphoma-tx-maintenance/> ;
  schema:dateModified "2026-09-29"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(10)62175-7>, <https://doi.org/10.1200/JCO.19.01073>, <https://doi.org/10.1056/NEJMoa1701769>, <https://doi.org/10.1200/JCO.2017.72.6984> ;
  onco:cancers <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/lenalidomide/>, <https://onco.cc/drugs/brentuximab-vedotin/> ;
  onco:terms <https://onco.cc/terms/maintenance-therapy/>, <https://onco.cc/terms/consolidation-therapy/> ;
  onco:trials <https://onco.cc/trials/aethera/> .